Remission and Dropout Rate of Anti-VEGF Therapy for Age-Related Macular Degeneration
Authors:
- 13 April 2011
- journal article
- research article
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 21 (6) , 777-782
Abstract
Purpose.: Anti-vascular endothelial growth factor (VEGF) therapy is a first-line treatment for age-related macular degeneration (AMD) but frequent visits and injections can be a burden for patients. The purpose of this study is to estimate the remission rate and tolerability of anti-VEGF therapy for AMD in a clinical setting. Methods.: We investigated 90 eyes of 87 patients with AMD who underwent anti-VEGF therapy and were followed for more than 6 months. Ranibizumab and pegaptanib were used as anti-VEGF agents. Initial therapy was any of the following: a single injection, 3 consecutive monthly injections, or combination therapy with verteporfin. Additional injections were given as-needed during follow-up. An injection-free period greater than 6 months at the final observation was regarded as cessation; the reason for cessation was studied for each patient. Clinical characteristics were compared between patents with and without cessation. Results.: The mean follow-up period was 12.8 months. Mean logMAR before and 6 months after the treatment was 0.89 and 0.83, respectively. Cessation was noted in 32 eyes of 31 patients (35.6%). Remission was achieved in 13 (40.6%) of these eyes. The other cases either did not wish to undergo further treatment or dropped out. Poor baseline visual acuity (VA) was associated with cessation. Conclusions.: With current anti-VEGF therapy, remission was achieved in a limited number of AMD cases. The high frequency of voluntary cessation warrants consideration of an alternative treatment and/or supportive care for those with poor baseline VA.Keywords
This publication has 21 references indexed in Scilit:
- Antiangiogenic Approaches to Age-Related Macular Degeneration TodayOphthalmology, 2009
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR StudyOphthalmology, 2009
- Anti-VEGF Agents in the Treatment of Neovascular Age-related Macular Degeneration: Applying Clinical Trial Results to the Treatment of Everyday PatientsAmerican Journal of Ophthalmology, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- The age-related macular degeneration radiotherapy trial (AMDRT): One year results from a pilot studyAmerican Journal of Ophthalmology, 2004
- Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Ophthalmic findingsSST report no. 11Ophthalmology, 2004
- Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With VerteporfinArchives of Ophthalmology (1950), 1999
- Laser Photocoagulation of Subfoveal Recurrent Neovascular Lesions in Age-Related Macular DegenerationArchives of Ophthalmology (1950), 1991
- Laser Photocoagulation of Subfoveal Neovascular Lesions in Age-Related Macular DegenerationArchives of Ophthalmology (1950), 1991